EnglishPURPOSE: Hormone receptors (HR) status in HER2 + breast cancer (BC) is a recognized stratification factor with relevant clinical implication. According to HR expression, HER2 + BC show different clinical characteristics, treatment sensitivity and prognosis. The interaction between HR and HER2 pathways remains incompletely understood. METHODS: Thirty-four HER2 + BC were included: 18 tumors with HER2+/HR + and 16 with HER2+/HR-. The expression of 770 genes and 13 molecular pathways were evaluated using Nanostring PanCancer Pathway panel performed on FFPE BC biopsies. RESULTS: Gene expression analysis identified 127 genes with significantly different expression between the two cohorts. 83% of these genes were overexpressed in HER2+/HR- cohort. Globally, 23% of them belonged to PI3K pathway (41 genes), 15% to Trascriptional regulation (26 genes) and 12% to MAPK (22 genes). Regarding pathway expression, PI3K, MAPK and NOTCH were significantly differently expressed between the two groups (p = 0.003, p = 0.0018 and p = 0.02, respectively), all of them were overexpressed in HER2+/HR- tumors. CONCLUSIONS: According to HR status, HER2 + tumors express different pathways profiles: the overexpression of PI3K, MAPK and NOTCH pathways in HER2+/HR- group could justify different survival outcomes and treatment sensitivity. The identification of tumor driver pathways may be a useful instrument for individualized pathway-directed therapies. Further clinical implications are warranted.
Differential molecular pathways expression in HER2 positive early breast cancer according to hormone receptor status / Omarini, C; Bettelli, S; Caprera, C; Manfredini, S; Barbolini, M; Moscetti, L; Isca, C; Toss, A; Barbieri, E; Cortesi, L; Kaleci, S; Maiorana, A; Tazzioli, G; Cascinu, S; Piacentini, F. - In: JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY. - ISSN 0171-5216. - (2019), pp. 1-1. [10.1007/s00432-018-02833-8]
| Data di pubblicazione: | 2019 | |
| Data di prima pubblicazione: | 2-gen-2019 | |
| Titolo: | Differential molecular pathways expression in HER2 positive early breast cancer according to hormone receptor status. | |
| Autore/i: | Omarini, C; Bettelli, S; Caprera, C; Manfredini, S; Barbolini, M; Moscetti, L; Isca, C; Toss, A; Barbieri, E; Cortesi, L; Kaleci, S; Maiorana, A; Tazzioli, G; Cascinu, S; Piacentini, F | |
| Autore/i UNIMORE: | ||
| Digital Object Identifier (DOI): | http://dx.doi.org/10.1007/s00432-018-02833-8 | |
| Rivista: | ||
| Pagina iniziale: | 1 | |
| Pagina finale: | 1 | |
| Codice identificativo ISI: | WOS:000462617300003 | |
| Codice identificativo Scopus: | 2-s2.0-85059460537 | |
| Codice identificativo Pubmed: | 30603906 | |
| Citazione: | Differential molecular pathways expression in HER2 positive early breast cancer according to hormone receptor status / Omarini, C; Bettelli, S; Caprera, C; Manfredini, S; Barbolini, M; Moscetti, L; Isca, C; Toss, A; Barbieri, E; Cortesi, L; Kaleci, S; Maiorana, A; Tazzioli, G; Cascinu, S; Piacentini, F. - In: JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY. - ISSN 0171-5216. - (2019), pp. 1-1. [10.1007/s00432-018-02833-8] | |
| Tipologia | Articolo su rivista |
File in questo prodotto:
| File | Descrizione | Tipologia | |
|---|---|---|---|
| DIFFERENTIAL.pdf | Articolo principale | Versione dell'editore (versione pubblicata) | Administrator Richiedi una copia |
Pubblicazioni consigliate
I metadati presenti in IRIS UNIMORE sono rilasciati con licenza Creative Commons CC0 1.0 Universal, mentre i file delle pubblicazioni sono rilasciati con licenza Attribuzione 4.0 Internazionale (CC BY 4.0), salvo diversa indicazione.
In caso di violazione di copyright, contattare Supporto Iris
Copyright © 2022